![](\"https:\/\/img-cdn.tnwcdn.com\/image?fit=796%2C417&url=https%3A%2F%2Fcdn0.tnwcdn.com%2Fwp-content%2Fblogs.dir%2F1%2Ffiles%2F2024%2F04%2FUntitled-design-46.jpg&signature=c189e058f6234d520bbe552d5daf8d88\")
<\/p>\nKnown as the Hybrid Closed Loop (HCL) system, the artificial pancreas is a device that significantly automates the management of blood sugar and insulin levels \u2014 a necessary process for those living with the condition.<\/p>\n
Specifically, the device continuously monitors blood sugar (glucose) levels, determines the amount of insulin needed, and transmits this information to a pump.<\/p>\n
This way, patients don\u2019t need to constantly monitor themselves with finger prick blood tests or by wearing a traditional glucose monitor. They can also rely on the technology<\/a> to receive insulin instead of having to inject it themselves.<\/p>\n TNW Conference 2024, June 20-21 – Join our Virtual Discount Hunt this week!<\/p>\n For a bit of Easter fun, we\u2019ve hidden a number of discount codes around our Conference website.<\/p>\n<\/div>\n<\/div>\n The NHS is now assessing which patients will benefit the most from the artificial pancreas, drawing from a pool of nearly 300,000 individuals, who are suffering from type 1 diabetes in the UK. The aim is to include both children and adults.<\/p>\n This world-first, nation-wide initiative builds on a successful trial of the technology in 2022, which showed that the device improved management of the disease across different age groups.<\/p>\n According to the NHS, the artificial pancreas can also prevent life-threatening symptoms such as hypoglycaemic and hyperglycaemic attacks. These occur\u00a0when the glucose levels are too low or too high, respectively. Another potential benefit is reducing the risk of type 1 diabetes progressing into type 2.<\/p>\n The rollout of the device across the country is expected to take five years. Currently, the NHS is spending around 10% of its budget on identifying and treating diabetes \u2014 which amounts to app<\/a>roximately \u00a310bn a year.<\/p>\n Smart devices for diabetes management are also being developed outside of public healthcare initiatives. The UK\u2019s startup world boasts companies such as SM24, Cellnovo, and Dia-Vit.\n <\/p><\/div>\n If you liked the article, do not forget to share it with your friends. Follow us on\u00a0Google News<\/a><\/span>\u00a0too, click on the star and choose us from your favorites.<\/span><\/strong><\/p><\/blockquote>\n If you want to read more like this article, you can visit our Technology category.<\/a><\/span><\/strong>\n<\/p><\/blockquote>\n\n